Post-Exposure Prophylaxis After Needlestick Injury: Regimen Selection
Both bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) 50/200/25 mg and the TLD regimen (tenofovir disoproxil fumarate/lamivudine/dolutegravir 300/300/50 mg) are equally acceptable preferred regimens for post-exposure prophylaxis following needlestick injury, and you can use either one. 1
Current CDC Guidelines (2025)
The most recent CDC guidelines explicitly list both regimens as co-preferred options for HIV post-exposure prophylaxis in adults and adolescents: 1
- Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) - single tablet formulation
- Dolutegravir plus (tenofovir alafenamide OR tenofovir disoproxil fumarate) plus (emtricitabine OR lamivudine) - which includes your TLD regimen 1
Both carry the same level of recommendation (very low certainty of evidence) and are considered equally appropriate first-line choices. 1
Key Advantages of Each Regimen
BIC/FTC/TAF (50/200/25 mg):
- Single tablet once daily - simplifies adherence 1
- Superior tolerability profile - lower rates of nausea/vomiting (15.4%), fatigue (9.6%), and diarrhea (7.7%) compared to other regimens 2
- Higher completion rates - 90.4% completion in real-world studies 2
- Better renal safety - tenofovir alafenamide has less nephrotoxicity than tenofovir disoproxil fumarate 1
- Preferred in pregnancy - listed as preferred regimen for pregnant individuals 1
TLD (TDF/3TC/DTG 300/300/50 mg):
- Lower cost - typically more affordable, especially in resource-limited settings 3
- Wider availability - more commonly stocked globally 3
- Established safety data - longer track record of use for PEP 4
- 90% completion rate with good tolerability when used for PEP 4
Selection Algorithm
Choose BIC/FTC/TAF when: 1
- Patient has renal dysfunction (eGFR 30-60 mL/min) - TAF is safer than TDF
- Patient has osteoporosis or bone density concerns - TAF causes less bone mineral density loss
- Simplifying pill burden is critical for adherence
- Patient is pregnant or of childbearing potential
- Cost is not a limiting factor
- Cost constraints exist
- BIC/FTC/TAF is not available
- Patient has normal renal function (eGFR ≥60 mL/min)
- No bone density concerns present
Critical Implementation Points
Timing and Duration:
- Initiate within 72 hours of exposure - the sooner the better, ideally within 2 hours 1, 5
- Complete full 28-day course regardless of which regimen is chosen 1, 3
- Prescribe the entire 28-day supply upfront rather than starter packs - this improves completion rates 3
Pre-Treatment Assessment:
- Perform HIV testing immediately using rapid or laboratory-based antigen/antibody combination test before starting PEP 1
- Assess renal function - calculate creatinine clearance to guide tenofovir formulation choice 1
- Screen for drug interactions with current medications 1
- Evaluate source patient HIV status when possible 1, 5
Follow-Up Testing:
Common Pitfalls to Avoid
Do not delay PEP initiation waiting for source patient testing - start immediately and adjust if source is found HIV-negative 1, 5
Do not use partial prescriptions or "starter packs" - this reduces completion rates; provide the full 28-day supply at initial visit 3
Do not prescribe TDF-containing regimens (including TLD) if creatinine clearance is <60 mL/min - use BIC/FTC/TAF instead 1
Do not assume all integrase inhibitor regimens are equivalent - while both are preferred, individual patient factors should guide selection 1
Bottom Line
You are not required to use the TLD regimen specifically. The 2025 CDC guidelines place BIC/FTC/TAF and dolutegravir-based regimens (including TLD) on equal footing as preferred options. 1 Select based on renal function, bone health, pregnancy status, cost, and availability. Both regimens demonstrate excellent efficacy when taken as prescribed for the full 28 days. 2, 4